XCEL-MT-OSTEO-ALPHA

Small molecule

BBanc de Sang i Teixits

XCEL-MT-OSTEO-ALPHA is one of 54 small molecule programs targeting Osteonecrosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisActive, not recruiting

Spinal FusionActive, not recruiting

OsteonecrosisPhase 1/Phase 2

Active, not recruiting

Spinal FusionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Spinal Fusion

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

MS Contin

HHikma Pharmaceuticals LLC

Approved

4 3

Vancocin

HHikma Pharmaceuticals LLC

Approved

2 4

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Decadron

AAspen Global Incorporated

Approved

2 6

Marcaine

IInnocoll

Approved

2 7

Toradol

JJavelin Pharmaceuticals

Approved

2 8

Sufenta

LLeaf Vertical Inc.

Approved

1 9

Forteo

AAlmaject

Approved

1 10

Vivarin

HHikma Pharmaceuticals LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mesenchymal Stromal Cells1 trial

Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones

Completed·BBanc de Sang i Teixits·Phase 1/2·NCT02230514·19 enrolled

Osteonecrosis1 trial

Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head

Completed·BBanc de Sang i Teixits·Phase 1/2·NCT01605383·23 enrolled

Spinal Fusion1 trial

Safety Study of Mesenchymal Stem Cells and Spinal Fusion

Completed·BBanc de Sang i Teixits·Phase 1/2·NCT01552707·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for XCEL-MT-OSTEO-ALPHA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XCEL-MT-OSTEO-ALPHA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XCEL-MT-OSTEO-ALPHA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Banc de Sang i Teixits company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBanc de Sang i Teixits

XCEL-MT-OSTEO-ALPHA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mesenchymal Stromal Cells1 trial

Osteonecrosis1 trial

Spinal Fusion1 trial

References

Drug Info

Quick Facts

Related News